Hospital-Level VAD Support and LVAD Care at an Illinois LTACH

Yes. RML Specialty Hospital is experienced in providing hospital-level care for patients with left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BiVADs) at our Chicago and Hinsdale campuses. Our care team works in direct coordination with the referring cardiac surgery programme to maintain device management protocols, monitor haemodynamic stability, and respond to any device-related or systemic complications that arise during the extended recovery period.

Once a VAD patient is medically stable and no longer requires the intensity of cardiac ICU monitoring, transfer to an LTACH like RML allows for continued hospital-level care, daily device monitoring, and extended recovery in a setting specifically designed for longer stays. LTACH care reduces ICU readmission risk, provides a more clinically appropriate environment for the recovery trajectory, and supports preparation for eventual rehabilitation or home discharge, at a lower overall cost to the healthcare system than continued ICU-level hospitalisation.

During VAD recovery, patients may require hospital-level management of complications including driveline infections at the device exit site, gastrointestinal bleeding associated with anticoagulation therapy, right ventricular failure in patients with left ventricular assist devices (LVADs), arrhythmias, thromboembolic events, and respiratory complications requiring monitoring or ventilator support. RML Specialty Hospital manages these complications in coordination with the referring cardiac surgery programme, maintaining device-specific protocols and responding to haemodynamic changes or device alerts. RML's depth of experience with medically complex cardiac patients positions it as one of the few LTACHs in the Chicago area capable of supporting the full clinical range of VAD recovery.

The length of stay for VAD patients at an LTACH typically exceeds 25 days, the Medicare-defined threshold that distinguishes long-term acute care hospitals from short-stay acute settings and governs LTACH reimbursement eligibility. At RML Specialty Hospital, the actual duration depends on each patient's clinical trajectory and recovery pathway. Patients on a bridge-to-transplant pathway may require an extended stay pending donor organ availability, while patients on a destination therapy pathway are supported toward rehabilitation readiness or a medically safe home discharge. RML provides care for as long as medically necessary in both cases.

Medicare Part A covers care at a Medicare-certified LTACH for VAD patients who meet the qualifying inpatient hospital stay requirement, a minimum of three consecutive inpatient days, and require ongoing hospital-level treatment for device management and associated medical complexity. Most patients recovering with a ventricular assist device meet these criteria, as VAD management requires daily physician oversight, anticoagulation monitoring, device parameter management, and the clinical capacity to respond to complications that exceed the capabilities of lower-acuity settings. RML Specialty Hospital is a Medicare-certified LTACH, and the admissions team can assist families and cardiac referring providers with coverage eligibility, secondary insurance coordination, and financial assistance options.